Active Pharmaceutical Ingredients (API) Market worth $248.3 billion by 2025

 Expected Growth in Revenue Generation:

The global active pharmaceutical ingredients market is projected to reach USD 248.3 billion by 2025 from USD 187.3 billion in 2020, at a CAGR of 5.8% during the forecast period.

Major Growth Boosting Factors:

The rising drug R&D, the increasing incidence of chronic diseases, the growing importance of generics, and the increasing uptake of biopharmaceuticals. On the other hand, unfavorable drug price control policies across various countries and high manufacturing costs are expected to restrain the growth of this market are the major factors driving the growth of this market.

Download PDF Brochure@ 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=263

In 2019, the innovative APIs segment accounted for the largest share of the active pharmaceutical ingredients market

Based on type, the active pharmaceutical ingredients market is segmented into innovative and generic APIs. The innovative APIs segment accounted for the largest share of the global active pharmaceutical ingredients market in 2019. Increased FDA approvals for new molecular entities, high price of innovative APIs as compared to the generic drugs, increased focus on R&D by the innovator API companies are the factors contributing towards the growth of the innovative APIs segment.

The oncology segment is expected to grow at the highest CAGR during the forecast period

Based on application, the active pharmaceutical ingredients market is segmented into communicable diseases, oncology, cardiovascular diseases, diabetes, pain management, chronic respiratory diseases, and other therapeutic application. neurology, immunology, hematology, critical care, pulmonology, hemato-oncology, rheumatology, and other applications. In 2019, the oncology segment is expected to register the highest CAGR during the forecast period. Growth in this market segment is driven by the increasing demand for highly potent APIs (HPAPIs) for the treatment of cancer.

North America was the largest regional market for active pharmaceutical ingredients market in 2019

The global active pharmaceutical ingredients market is segmented into North America, Europe, Asia, Latin America, and Rest of the World. In 2019, North America accounted for the largest share of the active pharmaceutical ingredients market, followed by Europe and the Asia. 

The large share of North America in the global market is attributed to the growing incidence of preventable chronic diseases, increasing government focus on generic drugs, rising demand for biologics and specialty drugs, and technological advancements in the manufacturing processes of APIs. However, the market in the Asia is expected to grow at the highest CAGR during the forecast period. This can be attributed to the low manufacturing costs, growth in the increase in disposable income, the high prevalence of lifestyle- and age-related diseases, and government efforts to reform healthcare industry.

Request Sample Pages@ 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=263

Global Leading Players:

The global active pharmaceutical ingredients market is highly consolidated. Prominent players in the active pharmaceutical ingredients market include Pfizer Inc. (US), Novartis International AG (Switzerland), Merck & Co. (US), Teva Pharmaceutical Industries Ltd. (Israel), Mylan N.V. (US), Boehringer Ingelheim (Germany), F. Hoffmann-La Roche AG (Switzerland), Sanofi (France), AbbVie (US), Eli Lilly and Company (US), AstraZeneca (UK), Bristol-Myers Squibb (US), and GlaxoSmithKline plc (UK).

Pharmaceutical Drug Delivery Market worth $2,206.5 billion by 2026

 About Drug Delivery:

Drug delivery is the method or process of administration of a pharmaceutical drug to safely attain its desired therapeutic effect. Advancements in drug delivery technologies offer several benefits, such as ease of use, convenience, and patient compliance.

Drug developers are focusing on suitable delivery and packaging options for increasing the efficiency of drugs and proposing improved patient compliance. Pharmaceutical and biopharmaceutical companies are focusing on R&D to develop new molecules for various therapeutic applications and drug delivery platforms. The companies invest majorly in R&Ds with an aim to deliver high-quality and innovative products to the market. R&D spending by biopharmaceutical companies has also increased over the years.

Download PDF Brochure@ 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1085

Overview of This Study:

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Expected Revenue Growth:

The global pharmaceutical drug delivery market is projected to reach USD 2,206.5 billion by 2026 from USD 1,656.9 billion in 2021, at a CAGR of 5.9% during the forecast period.

Major Growth Boosting Factors:

Growth in the pharmaceutical drug delivery market can largely be attributed to factors such as the rising prevalence of chronic diseases, growing biologics market, increasing R&D investments, and technological advancements & new product launches.

The topical drug delivery segment is expected to grow at the highest CAGR during the forecast period

Based on route of administration, the pharmaceutical drug delivery market is segmented into oral, pulmonary, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery. The topical drug delivery segment accounted for the highest CAGR of the pharmaceutical drug delivery market. This can be attributed to convenience and the ease of use, the ease of dosage, painless and non-invasive administration, and enhanced patient compliance.

The infectious diseases segment is expected to account for the largest share of the pharmaceutical drug delivery market

Based on application, the pharmaceutical drug delivery market is segmented into cancer, infectious diseases, cardiovascular diseases, diabetes, respiratory diseases, central nervous system disorders, autoimmune diseases, and other applications. In 2020, the infectious diseases segment accounted for the largest share of the pharmaceutical drug delivery market. The large share of this market segment can be attributed to the increasing prevalence of infectious diseases across the globe, increasing R&D expenditure for new drugs owing to the current COVID-19 pandemic scenario, and the rising number of FDA approvals for such drugs.

Asia Pacific is expected to account for the highest CAGR for players operating in the pharmaceutical drug delivery market

During the forecast period, the Asia Pacific is expected to be the fastest-growing regional market for pharmaceutical drug delivery. The rapid rise in the geriatric population, increased prevalence of chronic diseases, increased healthcare expenditure, increased R&D activities conducted in this region, growth in technological collaborations for pharmaceutical drug delivery technologies, favorable reimbursement policies, and growth in disposable incomes in the emerging Asian economies, such as China and India, are factors that are expected to drive the growth of the APAC market during the forecast period.

Request Sample Pages@ 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=1085

Global Key Players:

Major players in this market include Johnson & Johnson (US), Novartis International AG (Switzerland), F. Hoffmann-La Roche AG (Switzerland), Pfizer Inc. (US), Bayer AG (Germany), Antares Pharma, Inc. (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), 3M (US), Merck & Co., Inc. (US), Sanofi (France), Amgen, Inc. (US), AbbVie Inc. (US), Genmab A/S (Denmark), Gilead Sciences, Inc. (US), Boehringer Ingelheim (Germany), AstraZeneca plc. (UK), Eli Lilly and Company (US), Teva Pharmaceuticals Industries Ltd. (Israel), Bristol-Myers Squibb (US), Gerresheimer AG (Germany), Boston Scientific Corporation (US), Nimbus Therapeutics (US), Kite Pharma (US), and IDEAYA Biosciences, Inc. (US).

Drug Discovery Services Market worth $31.4 billion by 2026

 Expected Revenue Gains:

The global Drug discovery services market is projected to reach USD 31.4 billion by 2026 from USD 16.1 billion in 2021, at a CAGR of 14.3% during the forecast period of 2021 to 2026.

Download PDF Brochure@ 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=138732129

Major Growth Influencing Factors:

Growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, increasing demand for outsourcing analytical testing services, initiatives for research on rare diseases and orphan drugs, and the high cost of in-house drug development are creating new revenue pockets in the drug discovery services market.

On the other hand, stringent regulations governing drug discovery and animal usage are expected to restrain market growth to a certain extent. The shortage of skilled professionals poses a challenge for drug discovery service providers.

The chemistry services segment accounted for the largest share of the type segment in the drug discovery services market in 2020.

Based on type, the drug discovery services market is segmented into chemistry and biology services. The chemistry services segment commanded the largest share of this market in 2020. Growth in this market segment is largely due to the widespread application of chemistry in various early drug development phases to deliver robust candidates. The extensive usage of chemistry in academics, biotechnology companies, and large pharmaceutical companies also supports market growth.

The Hit-to-lead identification segment accounted for the largest share of the process segment in the drug discovery services market in 2020.

Based on process, the drug discovery services market is broadly classified into target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. Hit-to-lead identification segment accounted for the largest share of the drug discovery services market in 2020. Due to its vital role in drug discovery, hit-to-lead identification is the most revenue-generating process, and currently, many CROs are offering these services to pharmaceutical companies.

The Asia Pacific region is the fastest-growing region of the drug discovery services market in 2020.

Based on the region, the drug discovery market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is estimated to register the highest growth during the forecast period primarily due to expanding pharmaceutical and biopharmaceutical industry, rising number of CROs, implementation of favorable government policies, increasing number of newly established R&D and manufacturing facilities, and the presence of less-stringent regulations for drug discovery processes (especially in terms of using animals for research) in several APAC countries.

Request Sample Pages@ 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=138732129

Key Players:

Key players in the drug discovery service Market include Laboratory Corporation of America Holdings (US), Charles River Laboratories International Inc. (US), WuXi AppTec (China), and Thermo Fisher Scientific Inc (US).

In Situ Hybridization Market - Emerging Trends & Global Future Forecasts

 Overview of This Study:

This market research study involved the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global in situ hybridization market.

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify critical qualitative and quantitative information and to assess market prospects. The size of the ISH market was estimated through various secondary research approaches and triangulated with inputs from primary research to arrive at the final market size.

Download PDF Brochure@ 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=212028829

Research Methodologies Followed:

Secondary Research:

The secondary sources referred to for this research study include publications from government sources, such as WHO, OECD, GLOBOCAN, CDC, World Bank, and World Cancer Research Fund International. Secondary sources also include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global ISH market, which was validated through primary research.

Primary Research:

Extensive primary research was conducted after acquiring basic knowledge about the global in situ hybridization market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (such as personnel from the pharmaceutical and biopharmaceutical industry) and supply-side (such as C-level and D-level executives, product managers, marketing and sales managers of key manufacturers, distributors, and channel partners, among others) across four major regions—North America, Europe, the Asia Pacific, and the Rest of the World.

Approximately 80% and 20% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

Expected Revenue Gain, Globally:

The global in situ hybridization market size is projected to reach USD 1.3 billion by 2025 from USD 0.9 billion in 2020, at a CAGR of 7.4% during the forecast period.

Growth Boosting Factors:

The increasing incidence and prevalence of cancer and genetic disorders and awareness about companion diagnostics tests in ISH are the major factors driving the growth of this market.

Challenge: Lack of skilled professionals

To conduct an ISH-based test, it is very crucial to understand the molecular information of a chromosome or a gene. In addition, the reluctance to move from manual operations to automation is another challenge for market growth. Many providers find it challenging to make the transition to IT-based approaches from manual or traditional methods, or may not prefer to make the shift at all. Thus, the shortage of skilled, well-trained, and technically knowledgeable laboratory technicians to conduct ISH-based diagnosis is limiting their overall adoption, particularly in emerging markets.

Opportunity: Untapped markets in developing countries

In developed countries, high-quality molecular diagnostic tests are readily available. However, in developing countries, the cost of these diagnostic technologies is very high, which often makes them unaffordable for a large part of the population. Moreover, the lack of a commercial market for diagnostic procedures has resulted in the availability of a small number of diagnostic tests in developing countries.

North America accounted for the largest share of the global ISH market in 2019.

In 2019, North America accounted for the largest share of the ISH market. The increasing incidence of cancer and infectious diseases in the region is driving the focus on the development of personalized medicine and diagnostics tests. As a result, due to the strong demand for early cancer detection capabilities, the market for ISH-based diagnostic tests is expected to see steady growth. In addition, the region is home to a large base of clinical research laboratories and academic institutes.

Request Sample Pages@ 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=212028829

Key Players

Some of the key players include Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US) Danaher Corporation (US), Thermofisher Scientific (US), Abnova Corporation (Taiwan), BioGenex Laboratories (US), Bio-Techne Corporation (US), Biocare Medical, and Bio SB (US)

Laboratory Centrifuge Market - Expected Revenue Growth, Globally, by 2026

 Overview:

The study involved four major activities to estimate the current size of the laboratory centrifuges market. Exhaustive secondary research was done to collect information on the market and its different subsegments.

The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.

Expected Revenue Gains:

The laboratory centrifuges market is projected to reach USD 2.2 billion by 2026 from USD 1.8 billion in 2021, at a CAGR of 4.0% from 2021 to 2026.

Major Growth Boosting Factors:

The growth of this market is driven by increasing R&D investments and research grants; rising technological advancements and innovative rotor designs; increasing prevalence of infectious diseases leading to a higher volume of sample testing & cell-based research in laboratory centrifuges; and widening applications of laboratory centrifuges.

Download PDF Brochure@ 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=197749088

“Equipment are expected to hold the largest share of the laboratory centrifuges market, by product in 2021.”

Based on product, the laboratory centrifuges market is segmented into equipment and accessories. In 2020, the equipment segment accounted for the largest share of the laboratory centrifuges market. The large share of the equipment segment can be attributed to the requirement of the repeated purchase of accessories such as tubes, bottles, and buckets.

“Benchtop centrifuges are expected to hold the largest share of the laboratory centrifuges market, by model type in 2021.”

Based on model type, the laboratory centrifuges market is segmented into benchtop and floor-standing centrifuges. Among these, the benchtop centrifuges segment accounted for the larger market share since these centrifuges are cost-effective, versatile, easy to use, smaller in size, and considerably lighter in weight. These advantages have resulted in their increased adoption in the laboratory centrifuges market.

“General purpose centrifuges are expected to hold the largest share of the laboratory centrifuges market, by intended use in 2021.”

Based on intended use, the laboratory centrifuges market is segmented into clinical, preclinical, and general purpose centrifuges. The general purpose centrifuges segment accounted for the largest market share in 2020, owing to an increase in cellular research and the diagnosis of blood-related diseases are the major factors driving the growth of this market.

“Fixed-angle rotors are expected to hold the largest share of the laboratory centrifuges market, by rotor design in 2021.”

Based on rotor design, the laboratory centrifuges market is segmented into swinging-bucket rotors, fixed-angle rotors, vertical rotors, and other rotors based on rotor design. The fixed-angle rotors segment accounted for the largest share in the laboratory centrifuge equipment market in 2020. Factors such as increasing protein research activities and advantages associated with fixed-angle rotors such as fast runtime and excellent resolution are driving the growth of this market.

“Diagnostics segment are expected to hold the largest share of the laboratory centrifuges market, by application in 2021.”

Based on application, the laboratory centrifuges market is segmented into diagnostics, microbiology, cellomics, genomics, proteomics, blood component separation, and other applications (biochemical analysis and nanotechnology research). In 2020, the diagnostics segment accounted for the largest share of the laboratory centrifuges market, owing to the rising prevalence of various diseases and the focus on ensuring early disease diagnosis are the major factors driving the growth of the laboratory centrifuges market for this application segment.

“Hospitals are expected to hold the largest share of the laboratory centrifuges market, by end user in 2021.”

Based on end user, the laboratory centrifuges market is segmented into hospitals, biotechnology & pharmaceutical companies, and academic & research institutes. The hospitals segment accounted for the largest share in the laboratory centrifuges market in 2020. The increasing prevalence of diseases, coupled with the growing awareness regarding early diagnosis & treatment, increasing demand for blood, availability of novel and technologically advanced centrifuges for blood separation, and growing number of hospitals, especially in emerging countries, are some of the key factors driving the growth of the laboratory centrifuges market for hospitals.

“North America commanded the largest share of the laboratory centrifuges market in 2021.”

Based on region, the laboratory centrifuges market is segmented into North America, Europe, Asia Pacific, and Rest of the World (RoW). In 2020, North America commanded the largest share of the laboratory centrifuges market. The large share of North America can be attributed to the rising R&D investments by government bodies, increasing emphasis on better management and the treatment of infectious diseases, and rapid growth in the pharmaceutical industry.

Request Sample Pages@ 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=197749088

Key Players:

The major players operating in this market are Thermo Fisher Scientific, Inc. (US), Danaher Corporation (US), and Eppendorf AG (Germany), KUBOTA Corporation (Japan), Sigma Laborzentrifugen GmbH (Germany), NuAire (US), Sartorius AG (Germany), Andreas Hettich GmbH & Co.KG (Germany), HERMLE Labortechnik GmbH (Germany), Cardinal Health (US), Agilent Technologies (US), Centurion Scientific (UK), QIAGEN N.V. (Netherlands), and Bio-Rad Laboratories, Inc. (US).

Clinical Trial Supplies Market worth $ 2.9 billion by 2026

 Projected Revenue Gains:

The global clinical trial supplies market is projected to reach USD 2.9 billion by 2026 from USD 1.9 billion in 2021, at a CAGR of 8.5% during the forecast period of 2021 to 2026.

Future Growth Influencing Factors:

Market growth is largely driven by the increasing R&D expenditure in pharmaceutical and biopharmaceutical companies and the growing number of clinical trials conducted globally. However, the increasing cost of drug development and clinical trials is expected to restrain the growth of this market during the forecast period.

Download PDF Brochure@ 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=172240059

Overview:

This market research study involves the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global clinical trial supplies market.

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess market prospects. The clinical trial supplies market size was estimated through various secondary research approaches and triangulated with inputs from primary research.

The logistics and distribution segment accounted for the largest share of the services segment in the clinical trial supplies market in 2020.

Based on the service, the clinical trial supplies market is segmented into manufacturing; packaging, labeling, and blinding; comparator sourcing; logistics & distribution; storage & retention; and other services. Logistics & distribution services accounted for a share of around 26%. This segment is estimated to grow at the highest CAGR during the forecast period. Logistics & distribution and storage & retention are seen to be the leading segments with respect to the growth rate during the forecast period as a result of greater reliance on decentralization of clinical trials.

The oncology segment accounted for the largest share of the therapeutic area segment in the clinical trial supplies market in 2020

Based on the therapeutic area, the clinical trial supplies market is segmented into oncology, CNS & mental disorders, cardiovascular diseases, digestive disorders, infectious diseases, metabolic disorders, immunology, blood disorders, and other therapeutic areas (respiratory disorders, dermatological disorders, rare diseases, ENT diseases, Nephrology) Oncology is the largest segment in this market owing to the high and growing number of research studies on cancer therapeutics and the increasing number of companies focusing on bringing innovative cancer drugs into the market. The oncology segment is projected to grow at the highest CAGR during the forecast period.

The Asia Pacific region is the fastest-growing region of the clinical trial supplies market in 2020.

Based on the region, the clinical trial supplies market is broadly segmented into North America, Europe, the Asia Pacific, and the Rest of the World. The huge population base, presence of less stringent and harmonized regulatory frameworks, and limited competition make patient recruitment and seeking approval for clinical trials more convenient, less time-consuming, and cost-efficient in the APAC region.

This is attracting the attention of a majority of pharmaceutical, biopharmaceutical, and biotechnology giants to consider conducting their clinical trials in APAC countries. The Asia Pacific market is projected to register the highest growth during the forecast period due to the presence of many emerging players, less-stringent regulations, and the ease and cost-effectiveness of patient recruitment in APAC countries.

Request Sample Pages@ 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=172240059

Key Players:

The global clinical trial supplies market is competitive. Prominent players operating in the global clinical trial supplies market include Catalent, Inc. (US), Thermo Fisher Scientific (US), Piramal Pharma Solutions (India), Parexel International Corporation (US), and UDG Healthcare (Ireland).